Rabeca 20 mg (Tablet (Enteric Coated))

Unit Price: ৳ 7.00 (5 x 10: ৳ 350.00)
Strip Price: ৳ 70.00

Medicine Details

Category Details
Generic Rabeprazole sodium
Company Square pharmaceuticals plc

Brand name

Rabeca 20 mg Tablet

Therapeutic class

Proton Pump Inhibitor

Indications

  • Active duodenal ulcer
  • Active benign gastric ulcer
  • Symptomatic erosive or ulcerative gastro-esophageal reflux disease (GERD)
  • Gastro-esophageal Reflux Disease Long-term Management (GERD Maintenance)
  • Symptomatic treatment of moderate to very severe gastro-esophageal reflux disease (symptomatic GERD)
  • Zollinger-Ellison Syndrome
  • In combination with appropriate antibacterial therapeutic regimens for the eradication of Helicobacter pylori in patients with peptic ulcer disease

Pharmacology

Rabeprazole suppresses gastric acid secretion by inhibiting the gastric H⁺/K⁺-ATPase at the secretory surface of the gastric parietal cell.

Dosage

  • Active duodenal ulcer active benign gastric ulcer: 20 mg once daily in the morning
  • Erosive or ulcerative gerd: 20 mg once daily for 4-8 weeks
  • Gerd maintenance: 20 mg or 10 mg once daily
  • Symptomatic treatment of gerd: 10 mg once daily, or 10 mg once daily when needed in an on-demand regimen
  • Treatment of gerd in pediatric patients less than 15 kg: 5 mg once daily for 12 weeks with the option to increase to 10 mg if inadequate response
  • Treatment of gerd in pediatric patients 15 kg or more: 10 mg once daily for 12 weeks
  • Zollinger ellison syndrome: 60-120 mg/day, may require divided doses, treatment duration as clinically indicated
  • Eradication of h pylori: Rabeprazole sodium 20 mg twice daily, clarithromycin 500 mg twice daily, amoxicillin 1g twice daily for 7 days

Administration

To be taken in the morning, before eating, should not be chewed or crushed, swallow whole

Interaction

  • Interaction with compounds whose absorption is pH dependent may occur
  • Co-administration with ketoconazole or itraconazole may result in a significant decrease in antifungal plasma levels
  • No interaction with liquid antacids observed
  • PPIs, including rabeprazole, should not be co-administered with atazanavir

Contraindications

  • Hypersensitivity to the active substance or to any of the excipients
  • Contra-indicated in pregnancy and during breastfeeding

Side effects

  • Headache
  • Diarrhoea
  • Abdominal pain
  • Vomiting
  • Constipation
  • Dry mouth
  • Increased or decreased appetite
  • Muscle pain
  • Drowsiness
  • Dizziness

Pregnancy lactation

  • Pregnancy category: C
  • Excretion in human milk: Rabeprazole is likely to be excreted in human milk, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother

Precautions warnings

  • Symptomatic response to therapy with Rabeca does not preclude the presence of gastric or esophageal malignancy
  • Patients on long-term treatment should be kept under regular surveillance
  • Proton pump inhibitors may modestly increase the risk of hip, wrist, and spine fracture, particularly in the elderly or in presence of other recognized risk factors
  • A risk of cross-hypersensitivity reactions with other proton pump inhibitor or substituted benzimidazoles cannot be excluded
  • Hepatic enzyme abnormalities have been seen in clinical trials
  • No evidence of significant drug related safety problems was seen in a study of patients with mild to moderate hepatic impairment versus normal age and sex matched controls
  • Co-administration of atazanavir with Rabeca is not recommended
  • Treatment with proton pump inhibitors may possibly increase the risk of gastrointestinal infections such as Salmonella, Campylobacter and Clostridium difficile
  • Severe hypomagnesemia has been reported in patients treated with PPIs like rabeprazole for at least three months
  • Rabeprazole may reduce the absorption of vitamin B12
  • Proton pump inhibitors are associated with very infrequent cases of subacute cutaneous lupus erythematosus
  • Increased Chromogranin A (CgA) level may interfere with investigations for neuroendocrine tumors

Special populations

  • Renal hepatic impairment: No dosage adjustment necessary
  • Pediatric use: Not recommended for use in children due to a lack of data on safety and efficacy

Overdose effects

Effects are generally minimal, representative of the known adverse event profile and reversible without further medical intervention. No specific antidote is known. Rabeca is extensively protein bound and is, therefore, not dialysable. Treatment should be symptomatic and general supportive measures should be utilized.

Storage conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Chemical structure

  • Molecular formula: C18H21N3O3S
  • Chemical structure image: https://medex.com.bd/storage/res/g-res-942-rabeprazole-sodium-chemical-structure-atwg0Q4PlndQZhOY9GHX.svg

Commonly asked questions

  • What is used for: Duodenal ulcer, Gastric ulcer, GERD, Zollinger-Ellison Syndrome, Helicobacter pylori eradication
  • Side effects:
    • Diarrhea
    • Constipation
    • Nausea
    • Vomiting
    • Headache
    • Dizziness
    • Rash
    • Dry mouth
  • How to take: With food, usual dose is one tablet once a day, do not take more than the prescribed dose
  • Pregnancy breastfeeding: Not recommended during pregnancy or breastfeeding. Talk to your doctor about the risks and benefits.
  • Overdose: Call your doctor or the Poison Control Center immediately, overdose can cause symptoms such as drowsiness, confusion, and seizures.
  • Length of treatment: Depends on the condition being treated

Related Brands